AZN
NEUTRAL
$92.95
Live
AstraZeneca PLC · NASDAQ
Target $99.05
(+6.6%)
$61.24
52W Range
$96.51
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$288.2B
P/E
30.48
ROE
21.7%
Profit margin
16.2%
Debt/Equity
0.71
Dividend yield
1.71%
AI Analysis
AI-powered fundamental assessment
Confidence
75%
AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.
Key Strengths
Exceptional gross margin of 83.26% indicates strong pricing power and cost control
High ROE of 21.67% reflects efficient use of shareholder equity
Strong earnings growth of 78% YoY and solid revenue growth of 12% demonstrate momentum
Low Debt/Equity ratio of 0.71 suggests conservative capital structure
Analyst consensus is strong_buy with a target price of $99.05, implying 6.5% upside
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health, particularly in liquidity and earnings consistency
Current Ratio of 0.88 and Quick Ratio of 0.69 signal potential short-term liquidity pressure
Earnings volatility with multiple recent misses, including a -25.9% surprise in Q3 2025
Insider selling activity: $1.33M in sales with no buys in last 6 months
Technical trend score of 10/100 indicates near-term bearish momentum
AI Fair Value Estimate
Based on comprehensive analysis
$89.97
-3.2% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
57
Moderate
45
78
58
42
60
AI Verdict
Moderately positive with significant caution flags
Key drivers: Strong profitability and growth metrics, High analyst confidence, Earnings volatility and weak Piotroski score, Bearish insider and technical signals
Confidence
75%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 18.17 is reasonable for sector
- Intrinsic Value (Formula) of $89.97 close to current price
Watchpoints
- Current P/E of 30.48 is high
- Price/Sales of 4.96 and Price/Book of 3.14 indicate premium valuation
- Current price 106% above Graham Number ($45.06)
Future
78/100
Ref Growth rates
Positives
- Revenue Growth (YoY) of 12.00%
- Earnings Growth (YoY) of 78.00%
- Q/Q Earnings Growth of 77.30%
Watchpoints
- PEG Ratio not available, limiting growth-adjusted valuation
Past
58/100
Ref Historical trends
Positives
- 5Y price return of +92.9% shows strong long-term performance
- History of strong ROE and margins
Watchpoints
- Earnings beat rate of only 2/4 in last four quarters
- Average earnings surprise of -3.14% recently
- Multiple large negative surprises in 2021-2022
Health
42/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.71 is below sector average of 2.84
- ROA of 9.06% is solid
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Current Ratio of 0.88 < 1.0 signals liquidity risk
- Quick Ratio of 0.69 indicates limited liquid assets
Dividend
60/100
Ref Yield, Payout
Positives
- Dividend yield of 1.71% is modest but stable
- Payout ratio of 51.99% is sustainable
Watchpoints
- Dividend Strength score of 40/100 indicates limited reliability
- 5-Year Avg Yield not available, limiting trend analysis
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$92.95
Analyst Target
$99.05
Upside/Downside
+6.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AZN and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
Primary
|
+92.9% | +49.4% | +38.4% | +28.8% | +0.5% | -1.5% |
|
UNH
UnitedHealth Group Incorporated
Peer
|
-11.6% | -29.1% | -21.8% | -10.0% | +17.4% | +3.4% |
|
MRK
Merck & Co., Inc.
Peer
|
+93.0% | +22.1% | +44.3% | +36.7% | +0.6% | +1.6% |
|
TMO
Thermo Fisher Scientific Inc.
Peer
|
+6.7% | -9.7% | +18.7% | -9.2% | +7.5% | -3.3% |
|
AMGN
Amgen Inc.
Peer
|
+65.2% | +59.9% | +16.5% | +26.4% | -8.8% | +1.0% |
AZN
AstraZeneca PLC
Primary
5Y
+92.9%
3Y
+49.4%
1Y
+38.4%
6M
+28.8%
1M
+0.5%
1W
-1.5%
UNH
UnitedHealth Group Incorporated
Peer
5Y
-11.6%
3Y
-29.1%
1Y
-21.8%
6M
-10.0%
1M
+17.4%
1W
+3.4%
MRK
Merck & Co., Inc.
Peer
5Y
+93.0%
3Y
+22.1%
1Y
+44.3%
6M
+36.7%
1M
+0.6%
1W
+1.6%
TMO
Thermo Fisher Scientific Inc.
Peer
5Y
+6.7%
3Y
-9.7%
1Y
+18.7%
6M
-9.2%
1M
+7.5%
1W
-3.3%
AMG
Amgen Inc.
Peer
5Y
+65.2%
3Y
+59.9%
1Y
+16.5%
6M
+26.4%
1M
-8.8%
1W
+1.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
30.48
Forward P/E
18.17
PEG Ratio
N/A
P/B Ratio
3.14
P/S Ratio
4.96
EV/Revenue
2.9
EV/EBITDA
8.26
Market Cap
$288.2B
Profitability
Profit margins and return metrics
Profit Margin
16.17%
Operating Margin
24.11%
Gross Margin
83.26%
ROE
21.67%
ROA
9.06%
Growth
Revenue and earnings growth rates
Revenue Growth
+12.0%
Earnings Growth
+78.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+77.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.71
Moderate
Current Ratio
0.88
Weak
Quick Ratio
0.69
Poor
Cash/Share
$5.28
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-10
$N/A
2025-11-06
$1.19
+4.9% surprise
2025-07-29
$1.09
-25.9% surprise
2025-04-29
$1.25
+11.6% surprise
Healthcare Sector Comparison
Comparing AZN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
30.48
This Stock
vs
75.44
Sector Avg
-59.6%
(Discount)
Return on Equity (ROE)
21.67%
This Stock
vs
-88.14%
Sector Avg
-124.6%
(Below Avg)
Profit Margin
16.17%
This Stock
vs
-16.28%
Sector Avg
-199.3%
(Weaker)
Debt to Equity
0.71
This Stock
vs
2.66
Sector Avg
-73.3%
(Less Debt)
Revenue Growth
12.0%
This Stock
vs
124.04%
Sector Avg
-90.3%
(Slower)
Current Ratio
0.88
This Stock
vs
4.47
Sector Avg
-80.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
NEUTRAL | $288.2B | 30.48 | 21.7% | 16.2% | $92.95 | |
|
UNH
UnitedHealth Group Incorporated
|
NEUTRAL | $293.61B | 24.43 | 12.5% | 2.7% | $323.48 | Compare |
|
MRK
Merck & Co., Inc.
|
NEUTRAL | $299.79B | 16.66 | 36.9% | 28.1% | $121.25 | Compare |
|
TMO
Thermo Fisher Scientific Inc.
|
NEUTRAL | $191.01B | 28.99 | 13.0% | 15.0% | $513.98 | Compare |
|
AMGN
Amgen Inc.
|
NEUTRAL | $189.67B | 24.71 | 106.1% | 21.0% | $351.85 | Compare |
AZN
AstraZeneca PLC
NEUTRAL
Mkt Cap
$288.2B
P/E
30.5
ROE
21.7%
Price
$92.95
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-12 | Sarin (Aradhana M.D.) | Sale | 15,000 | $1,329,450 | |
| 2025-09-09 | Knudsen (Karen) | Purchase | 9 | $729 |
Sarin (Aradhana M.D.)
2025-11-12
15,000 shares
·
$1,329,450
Knudsen (Karen)
2025-09-09
9 shares
·
$729
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning AZN from our newsroom.
Newest → oldest
No matching news yet.